Unraveling the role of proteases in cancer

Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, 540 E. Canfield, Detroit, MI 48201, USA.
Clinica Chimica Acta (Impact Factor: 2.82). 03/2000; 291(2):113-35. DOI: 10.1016/S0009-8981(99)00224-7
Source: PubMed

ABSTRACT Investigators have been studying the expression and activity of proteases in the final steps of tumor progression, invasion and metastasis, for the past 30 years. Recent studies, however, indicate that proteases are involved earlier in progression, e.g., in tumor growth both at the primary and metastatic sites. Extracellular proteases may co-operatively influence matrix degradation and tumor cell invasion through proteolytic cascades, with individual proteases having distinct roles in tumor growth, invasion, migration and angiogenesis. In this review, we use cathepsin B as an example to examine the involvement of proteases in tumor progression and metastasis. We discuss the effect of interactions among tumor cells, stromal cells, and the extracellular matrix on the regulation of protease expression. Further elucidation of the role of proteases in cancer will allow us to design more effective inhibitors and novel protease-based drugs for clinical use.

Download full-text


Available from: Mamoun Ahram, Sep 02, 2015
  • Source
    • "In this context, nanocarriers should release their drug payload only in response to specific physiological changes naturally occurring within tumors, such as the presence of high concentrations of matrix metalloproteases (MMPs) (Basel et al., 2011; Nagase and Woessner, Jr., 1999; Kugler, 1999; Sawant et al., 2006). MMPs are proteolytic enzymes overexpressed in tumors, which are involved in a number of biological mechanisms and catalytic activities related with tumor progression (Koblinski et al., 2000; Zucker, 1988). In particular, MMP2 (also known as gelatinase A; Mw: 72 kDa) hydrolyzes type IV collagen, which is a major constituent of tumor extracellular matrix (ECM), thus resulting in enhanced tumor progression (Klein et al., 2004), invasion and angiogenesis (Holle et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A major issue in chemotherapy is the lack of specificity of many antitumor drugs, which cause severe side effects and an impaired therapeutic response. Here we report on the design and characterization of model tumor activated prodrug – conjugated polystyrene (PS) nanoparticles (TAP-NPs) for the release of doxorubicin (Dox) triggered by matrix metalloprotease-2 (MMP2) enzyme, which is overexpressed in the extracellular matrix of tumors. In particular, TAP NPs were produced by attaching Dox to poly(ethylene glycol) (PEG) through two MMP2–cleavable enzymes. The resulting adduct was then tethered to PS NPs. Results showed that Dox release was actually triggered by MMP2 cleavage and was dependent on enzyme concentration, with a plateau around 20 nM. Furthermore, significant cell cytotoxicity was observed towards three cell lines only in the presence of MMP2, but not in cells without enzyme pre-treatment, even after NP internalization by cells. These findings indicate the potential of TAP-NP as suitable nanocarriers for an on demand, tumor – specific delivery of antitumor drugs after the response to an endogenous stimulus. Further advancements will focus on the translation of this production technology to biodegradable systems for the safe transport of cytotoxic drug to tumor tissues. Biotechnol. Bioeng. © 2014 Wiley Periodicals, Inc.
    Biotechnology and Bioengineering 03/2015; 112(3). DOI:10.1002/bit.25454 · 4.16 Impact Factor
  • Source
    • "The rapidly grown cancer cells turn into tumors, which compete with other somatic cells for space and nutrient. The tumor oppresses normal tissues, affects the normal function of surrounding tissues, and invades adjacent blood vessels or the lymphatic system which leads to metastasis [8]. In fact, many cancer patients do not decease from the exacerbation of the primary tumors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluates the effect of mushroom beta-glucans (MBGS) derived from solid culture of Ganoderma lucidum on tumor inhibition by examining size of the primary tumor and rate of metastasis in Lewis lung carcinoma (LLC) bearing mice (C57BL/6), given oral administration of MBGS with radiation therapy. A previous result showed that MBGS enhances NK cell-mediated cytotoxicity in mice without LLC bearing in advance. Furthermore, applications of MBGS in conjunction with radiation therapy were effective in controlling tumor growth, and rate of metastasis, life threatening, and can potentially serve as a protective factor for wounds and hair loss that resulted from the overgrowth of primary tumor in LLC bearing mice.
    Evidence-based Complementary and Alternative Medicine 04/2014; 2014:252171. DOI:10.1155/2014/252171 · 1.88 Impact Factor
  • Source
    • "Included in this group are metalloproteinases such as matrix metalloproteinases (MMPs) and serine proteases such as plasmin, among others.1 These proteins have the capacity to completely remodel the extracellular matrix (ECM) and can therefore alter a variety of biologic processes, including angiogenesis, growth factor bioavailability, cytokine modulation, receptor shedding, cell migration, proliferation, invasion, and apoptosis.2,3 Not surprisingly, these proteases and their protein inhibitors have been implicated in many diseases, including cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The extracellular matrix (ECM) is the complex network of proteins that surrounds cells in multicellular organisms. Due to its diverse nature and composition, the ECM has a multifaceted role in both normal tissue homeostasis and pathophysiology. It provides structural support, segregates tissues from one another, and regulates intercellular communication. Furthermore, the ECM sequesters a wide range of growth factors and cytokines that may be released upon specific and well-coordinated cues. Regulation of the ECM is performed by the extracellular proteases, which are tasked with cleaving and remodeling this intricate and diverse protein matrix. Accordingly, extracellular proteases are differentially expressed in various tissue types and in many diseases such as cancer. In fact, metastatic dissemination of tumor cells requires degradation of extracellular matrices by several families of proteases, including metalloproteinases and serine proteases, among others. Extracellular proteases are emerging as strong candidate cancer biomarkers for aiding and predicting patient outcome. Not surprisingly, inhibition of these protumorigenic enzymes in animal models of metastasis has shown impressive therapeutic effects. As such, many of these proteolytic inhibitors are currently in various phases of clinical investigation. In addition to direct approaches, aberrant expression of extracellular proteases in disease states may also facilitate the selective delivery of other therapeutic or imaging agents. Herein, we outline extracellular proteases that are either bona fide or probable prognostic markers in breast cancer. Furthermore, using existing patient data and multiple robust statistical analyses, we highlight several extracellular proteases and associated inhibitors (eg, uPA, ADAMs, MMPs, TIMPs, RECK) that hold the greatest potential as clinical biomarkers. With the recent advances in high-throughput technology and targeted therapies, the incorporation of extracellular protease status in breast cancer patient management may have a profound effect on improving outcomes in this deadly disease.
    Breast Cancer: Targets and Therapy 03/2014; Volume 2014(6):81 - 91. DOI:10.2147/BCTT.S46020
Show more